The AIDS Malignancy Consortium (AMC)
is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for AIDS-associated malignancies. The AMC is composed of 14 main Clinical Trials Sites and their affiliates, and an Operations and Statistical Center. The AMC is committed to enhancing therapeutic options for patients with AIDS-associated malignancies.

The AMC is composed of 5 Working Groups (WG), as well as an Administrative Office, a Statistical Office and an Operations and Data Management Office. Collectively, these components develop and oversee the scientific agenda, manage the group’s portfolio of pathogenesis-based clinical trials and correlative studies, and develop new protocols.

Three of these working groups are disease specific working groups: Kaposi’s sarcoma WG, Lymphoma WG, and Human Papillomavirus (HPV) WG. A Laboratory WG oversees the Core Laboratories and develops laboratory studies to answer important pathogenesis or correlation questions in conjunction with the three disease-specific WGs and an International Working Group.
AIDS Malignancy HIV malignancy HIV Lymphoma AIDS Lymphoma
Kaposi's Sarcoma KS HPV Anal Cancer HIV cancer AIDS cancer